DSGN Design Therapeutics, Inc.
Healthcare$11.40+3.92%ClosedMarket Cap: $712.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.09
P/S
0.00
EV/EBITDA
-9.21
DCF Value
$0.27
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.1%
ROA
-30.3%
ROIC
-35.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-19.7M | $-17.6M | $— | — |
| Q4 null | $0.00 | Infinity% | $-18.2M | $-16.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-79.5M | $-69.8M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-19.3M | $-17.0M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-21.6M | $-19.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-20.4M | $-17.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.7M | $-13.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-62.4M | $-49.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-16.2M | $-13.0M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-15.0M | $-11.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-14.4M | $-11.1M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-15.1M | $-11.8M | $-0.21 | — |